Vitiligo in a patient during Chemotherapy with Dasatinib

• Joonsoo PARK

  Department of Dermatology, School of Medicine, Daegu Catholic University, Republic of Korea

• YongWoo CHOI

  Department of Dermatology, School of Medicine, Daegu Catholic University, Republic of Korea

抄録

　Dasatinib is a divond-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, c-Kit tyrosine kinases, and Src. While skin hypopigmentation is a well-recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib yet. We report a rare case of vitiligo induced by dasatinib. A 41-year-old male with a history of chronic myeloid leukemia was initiated on dasatinib as part of a treatment. After 2 months of treatment, he developed skin hypopigmentation on left shoulder and arm area. With skin biopsy, the histopathologic diagnosis with HMB45 and Melan-A staining was confirmed by vitiligo. The patient with dasatinib-induced vitiligo continued to receive treatment with the drug during which time areas of skin hypopigmentation persisted and progressed. We reported rare case of vitiligo induced by treatment of dasatinib.

収録刊行物

• 日本毒性学会学術年会

  日本毒性学会学術年会 45.1 (0), P-134-, 2018

  日本毒性学会

詳細情報

• CRID: 1390845712986421760
• NII論文ID: 130007432144
• DOI: 10.14869/toxpt.45.1.0_p-134
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可